Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

Summary

The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

Timeline

Start

2020-08-04

Primary completion

2027-04-06

Completion

2027-04-06

Drugs

Indications